Please assess the completion status of the following clinical trial:

Trial Title: Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* Clinical diagnosis of BPH~* AUA-SI \>=12 \[American Urological Association Symptom Index\]~* Qmax \> 5ml/sec and \<=15ml/sec and minimum voided volume of \>=125ml~* Prostate volume \>=30cm(3)~Exclusion:~* Post void residual volume \>250ml~* History or evidence of prostate cancer~* Total serum PSA \<1.5ng/ml or \>10.0ng/ml (Prostate specific antigen)~* Previous prostatic surgery or other invasive procedures to treat BPH.~* History of AUR (Acute Urinary Retention) within 3 months~* History of flexible/rigid cystoscopy or other instrumentation of the urethra within 7 days~* Any causes other than BPH, which may in the judgement of the investigator, result in urinary symptoms or changes in flow rate~* History of hepatic impairment or abnormal liver function tests~* Use of any 5a-reductase inhibitors ,any drugs with antiandrogenic properties or other drugs noted for gynaecomastia effects, or could affect prostate volume, within past 6 months and throughout the study~* Use of alpha-receptor blockers within 2 weeks and throughout the study.~* Use of phytotherapy for BPH within 2 weeks and/or predicted to need phytotherapy during the study.~* Concurrent use of anabolic steroids~* Use of any alpha-adrenergic agonists or cholinergics within 48 hours prior to uroflowmetry assessment.~* Hypersensitivity to any 5a-reductase inhibitor or other chemically-related drugs.~* Actively trying to procreate or unwilling to wear a condom during intercourse with a woman of childbearing potential for duration of participation in this study and 16 weeks following treatment.~* History or current evidence of drug or alcohol abuse within the previous 12 months.~* History of any illness that in the opinion of the investigator might confound the results of the study or poses additional risk to the patient.~* Any unstable, serious co-existing medical condition(s) including, but not limited to, myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, of cerebrovascular accident within 6 months prior to Screening visit; uncontrolled diabetes or peptic ulcer disease which is uncontrolled by medical management.~* History of renal insufficiency, or serum creatinine \>1.5xULN (Upper Limit of Normal )~* Participation in any investigational or marketed drug trial within 30 days and during the course of the study.

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): dutasteride 0.5mg once daily orally
- B (Type: PLACEBO_COMPARATOR): Placebo matched once daily orally

Based on this trial design, predict the completion outcome and termination type (if applicable).